PCSA
Income statement / Annual
Last year (2025), Processa Pharmaceuticals Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Processa Pharmaceuticals Inc's net income was -$13.56 M.
See Processa Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$5.00 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$874.01 K
|
$0.00
|
$882.06 K
|
$0.00
|
$0.00
|
$0.00
|
$1.38 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
-$874.01 K
|
$0.00
|
-$882.06 K
|
-$877.90 K
|
-$630.09 K
|
-$1.87 K
|
$3.62 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.72
|
| Research and Development Expenses |
$7.81 M
|
$7.27 M
|
$5.80 M
|
$10.71 M
|
$6.88 M
|
$11.08 M
|
$2.32 M
|
$3.09 M
|
$926.12 K
|
$6.56 K
|
| General & Administrative Expenses |
$6.18 M
|
$4.78 M
|
$5.66 M
|
$0.00
|
$4.69 M
|
$0.00
|
$1.61 M
|
$1.44 M
|
$876.32 K
|
$384.52 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.18 M
|
$4.78 M
|
$5.66 M
|
$8.68 M
|
$4.69 M
|
$3.18 M
|
$1.61 M
|
$1.44 M
|
$876.32 K
|
$384.52 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$566.58 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.85 M
|
| Operating Expenses |
$13.99 M
|
$12.05 M
|
$11.46 M
|
$19.38 M
|
$12.13 M
|
$14.25 M
|
$3.94 M
|
$4.52 M
|
$1.80 M
|
$1.93 M
|
| Cost And Expenses |
$13.99 M
|
$12.05 M
|
$11.46 M
|
$20.26 M
|
$12.13 M
|
$15.14 M
|
$3.94 M
|
$4.52 M
|
$1.80 M
|
$76.53 K
|
| Interest Income |
$109.49 K
|
$201.09 K
|
$335.54 K
|
$101.20 K
|
$11.99 K
|
$3.17 K
|
$11.55 K
|
$18.30 K
|
$5.18 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$362.00
|
$281.12 K
|
$36.66 K
|
$161.21 K
|
$35.69 K
|
$245.38 K
|
| Depreciation & Amortization |
$1.20 K
|
$782.00
|
$222.00
|
$788.50 K
|
$790.97 K
|
$882.06 K
|
$877.90 K
|
$630.09 K
|
$1.87 K
|
$1.38 K
|
| EBITDA |
-$13.56 M |
-$11.85 M |
-$11.12 M |
-$26.64 M |
-$10.78 M |
-$14.25 M |
-$3.05 M |
-$3.88 M |
-$1.80 M |
-$337.18 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-67.44
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-384.3
|
| Total Other Income/Expenses Net |
$424.67 K
|
$201.09 K
|
$335.54 K
|
-$7.17 M
|
$175.40 K
|
-$277.95 K
|
-$25.11 K
|
-$142.91 K
|
-$53.88 K
|
$4.45 K
|
| Income Before Tax |
-$13.56 M
|
-$11.85 M
|
-$11.12 M
|
-$27.42 M
|
-$11.96 M
|
-$15.41 M
|
-$3.96 M
|
-$4.67 M
|
-$1.86 M
|
-$337.18 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-67.44
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$530.61 K
|
-$1.00 M
|
-$602.72 K
|
-$902.80 K
|
-$18.19 K
|
-$1.20 K
|
| Net Income |
-$13.56 M
|
-$11.85 M
|
-$11.12 M
|
-$27.42 M
|
-$11.43 M
|
-$19.04 M
|
-$3.36 M
|
-$3.77 M
|
-$1.86 M
|
-$335.98 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-67.2
|
| EPS |
-10.36 |
-96.75 |
-212 |
-851.19 |
-373 |
-1269.25 |
-304.25 |
-355 |
-200 |
-747.25 |
| EPS Diluted |
-10.36 |
-96.75 |
-212 |
-851.19 |
-373 |
-1269.25 |
-304.25 |
-355 |
-200 |
-747.25 |
| Weighted Average Shares Out |
$1.31 M
|
$122.40 K
|
$52.46 K
|
$32.22 K
|
$30.64 K
|
$15.00 K
|
$11.05 K
|
$10.66 K
|
$9.31 K
|
$1.20 K
|
| Weighted Average Shares Out Diluted |
$1.31 M
|
$122.40 K
|
$52.46 K
|
$32.22 K
|
$30.64 K
|
$15.00 K
|
$11.05 K
|
$10.66 K
|
$9.31 K
|
$1.20 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
